89bio

Our CEO, Rohan Palekar, spoke with BiotechTV reporter Brian Orelli, PhD during the AASLD Annual Meeting and shared details of new post-hoc analyses from our Phase 2b ENLIVEN study evaluating our investigational treatment for MASH patients with advanced fibrosis. Check out the full interview to learn more. #TLM24 #MASH

Hear from our CEO, Rohan Palekar about his perspective on what it will take to reverse fibrosis in patients with advanced metabolic dysfunction-associated steatohepatitis (MASH) in his recent Endpoints News article. Rohan also shares the latest developments in potential treatment options, including our lead treatment candidate for MASH now in Phase 3 clinical trials. Read the full article here: https://lnkd.in/g8V_Gbwy #Innovation #MASH #LiverDisease?

??Hot off the press! 89bio is presenting new information from our ENLIVEN Phase 2b study, including new analyses on progression to cirrhosis and correlation of noninvasive tests to histological disease activity and endpoints.?? ? Read more on the new analyses and join us live at Booth 1610 during the 75th AASLD Annual Meeting to discuss: https://lnkd.in/g5rNTfyc #Biotech #Innovation #TLM24 #MASH?

?? The 75th AASLD Annual Meeting starts tomorrow! Be sure to visit us at BOOTH 1610 to learn more about new analyses of data from our ENLIVEN Phase 2b study in metabolic dysfunction-associated steatohepatitis (MASH) patients with advanced fibrosis. ? ?? Details about our four poster presentations here: https://lnkd.in/gU7Sm8Ar #TLM24 #Biotech #Innovation #MASH?

Today we announced our Q3 2024 financial results and a business update. We are excited to share our progress this quarter and celebrate the hard work of #Team89bio. Read our release for the details: https://lnkd.in/gqxymdN9 #The89way #Biotech #LiverDisease?

?? We will be participating in the UBS Global Healthcare Conference in Los Angeles from November 11 – 14. If you plan on attending, be sure to say hello to our team. Details here: https://lnkd.in/gNz8R3j4 #Biotech #LiverDisease??

The 89bio team will be participating in the Liver Life Walk hosted by the American Liver Foundation (ALF). This walk is an opportunity to raise awareness of liver disease and support the 100 million Americans that are affected. We look forward to connecting with members of the community at this inspirational event! Learn more and sign up for the event here: https://lnkd.in/g4MH_QXD #LiverLifeWalk #MASH #LiverDisease ?

At 89bio, we prioritize our people-first culture to ensure we are a united and collaborative front. Back in August, we hosted a company offsite and more recently an All-Company Week in which we strengthened our team connections, embodied 89bio core values, and solidified our goals as a team. Fostering an environment where team members are supported, celebrated, and encouraged to evolve in their role is #The89way. Interested in joining our team? Visit our website to learn about our current job openings: https://lnkd.in/gmTuunUm #The89way #Team89bio

Severe hypertriglyceridemia or SHTG, is a condition that occurs when triglycerides rise significantly above normal levels. Although there are many factors that may cause SHTG, the risks remain the same. The potential impact of SHTG can have severe consequences throughout the body. SHTG increases the risk of acute pancreatitis, a serious condition that can result in hospitalization or even death. Learn more about our mission to expand treatment options for patients with SHTG, and other liver diseases: https://lnkd.in/gM-PXEuU

We are excited to share we will be presenting four poster presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Diego that showcase new analyses of data from our ENLIVEN Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH). To learn more about our poster presentations, read our release: https://lnkd.in/gU7Sm8Ar #AASLD #MASH #Innovation #Biotech